Ads by Google
Prostate Cancer Treatment and Symptoms
Many men are not aware of the pros and cons of taking a prostate cancer test and do not make informed decisions. Now, new research suggests that health officials can help men choose more wisely by making presentations to them in groups in their communities.
Researchers found that they could boost levels of "informed decision-making" and encourage consultation with doctors by speaking at places like churches, YMCAs and barbershops.
Researchers have identified traits of an aggressive type of prostate cancer that occurs in about 10 percent of men who have the disease.
Compendia Bioscience announced the central role of their flagship product Oncomine in the discovery and identification of SPINK1 as a key new therapeutic target and biomarker for prostate cancer.
Researchers have shown that by blocking a signaling protein, they can prevent prostate cancer cells from metastatic dissemination.
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone -- the hormone that fuels prostate-cancer growth -- via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. Findings suggest androgen production occurs within metastatic prostate tumors.
Using a special ultrasound technique to spot areas of blood flow in the prostate gland may substantially reduce the number of unnecessary biopsies.
Those concerned with the prostate cancer risk may want to know that the form of tomato product one eats could be the key to unlocking its prostate cancer-fighting potential.
Mike Strong, a health minister for Hallelujah Acres, was only 52 when an annual physical revealed his Prostate Specific Antigen (PSA) was 31 (normal is 4 or under). Although he had no symptoms, a biopsy confirmed that he had cancer.
His doctor urged him to have a radical prostectomy to remove his prostate and surrounding tissue. He refused, but did agree to take the testosterone blocker Lupron for one year.
The Lupron made him feel extremely tired and he lost all sexual desire. The drug temporarily lowered his PSA, but it jumped to 46 when he stopped it.
Modern 3-D computed tomography is an effective method for locating the prostatic apex for radiation therapy treatment planning in prostate cancer patients because it eliminates the need for an invasive procedure and the related side effects.
There is strong need for prostate cancer reliable clinical predictors for the progression of disease.
Men aged 75-80 with prostate-specific antigen (PSA) levels less than 3 ng/ml may be able to discontinue their regular prostate cancer screenings.
Men with greater access to prostate cancer screenings and treatment have better outcomes from the disease.